243 related articles for article (PubMed ID: 29168006)
21. Diagnostic performance of initial enhancement analysis using ultra-fast dynamic contrast-enhanced MRI for breast lesions.
Goto M; Sakai K; Yokota H; Kiba M; Yoshida M; Imai H; Weiland E; Yokota I; Yamada K
Eur Radiol; 2019 Mar; 29(3):1164-1174. PubMed ID: 30088064
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis of MRI radiomics-based diagnosis for BI-RADS 4 breast lesions.
Lin J; Zheng H; Jia Q; Shi J; Wang S; Wang J; Ge M
J Cancer Res Clin Oncol; 2024 May; 150(5):254. PubMed ID: 38748373
[TBL] [Abstract][Full Text] [Related]
23. Frequency and Cancer Yield of BI-RADS Category 3 Lesions Detected at High-Risk Screening Breast MRI.
Edmonds CE; Lamb LR; Mercaldo SF; Sippo DA; Burk KS; Lehman CD
AJR Am J Roentgenol; 2020 Feb; 214(2):240-248. PubMed ID: 31799867
[No Abstract] [Full Text] [Related]
24. Risk of malignancy in palpable solid breast masses considered probably benign or low suspicion: implications for management.
Giess CS; Smeglin LZ; Meyer JE; Ritner JA; Birdwell RL
J Ultrasound Med; 2012 Dec; 31(12):1943-9. PubMed ID: 23197547
[TBL] [Abstract][Full Text] [Related]
25. Growing BI-RADS category 3 lesions on follow-up breast ultrasound: malignancy rates and worrisome features.
Ha SM; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
Br J Radiol; 2018 Jul; 91(1087):20170787. PubMed ID: 29658793
[TBL] [Abstract][Full Text] [Related]
26. Breast MRI as an adjunct to mammography: Does it really suffer from low specificity? A retrospective analysis stratified by mammographic BI-RADS classes.
Benndorf M; Baltzer PA; Vag T; Gajda M; Runnebaum IB; Kaiser WA
Acta Radiol; 2010 Sep; 51(7):715-21. PubMed ID: 20707656
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and Predictive Value of BI-RADS 3, 4, and 5 Lesions Detected on Breast MRI: Correlation with Study Indication.
Chikarmane SA; Tai R; Meyer JE; Giess CS
Acad Radiol; 2017 Apr; 24(4):435-441. PubMed ID: 27955878
[TBL] [Abstract][Full Text] [Related]
28. Is a one-year follow-up an efficient method for better management of MRI BI-RADS(®) 3 lesions?
Boisserie-Lacroix M; Ziadé C; Hurtevent-Labrot G; Ferron S; Brouste V; Lippa N
Breast; 2016 Jun; 27():1-7. PubMed ID: 27212693
[TBL] [Abstract][Full Text] [Related]
29. Interobserver Variability Between Breast Imagers Using the Fifth Edition of the BI-RADS MRI Lexicon.
Grimm LJ; Anderson AL; Baker JA; Johnson KS; Walsh R; Yoon SC; Ghate SV
AJR Am J Roentgenol; 2015 May; 204(5):1120-4. PubMed ID: 25905951
[TBL] [Abstract][Full Text] [Related]
30. Magnetic resonance imaging of the breast as a problem-solving method: to be or not to be?
Oztekin PS; Kosar PN
Breast J; 2014; 20(6):622-31. PubMed ID: 25200378
[TBL] [Abstract][Full Text] [Related]
31. Concordance of BI-RADS Assessments and Management Recommendations for Breast MRI in Community Practice.
Lee AY; Ichikawa L; Lee JM; Lee CI; DeMartini WB; Joe BN; Wernli KJ; Sprague BL; Herschorn SD; Lehman CD
AJR Am J Roentgenol; 2016 Jan; 206(1):211-6. PubMed ID: 26700354
[TBL] [Abstract][Full Text] [Related]
32. Contrast-enhanced 3.0-T breast MRI for characterization of breast lesions: increased specificity by using vascular maps.
Schmitz AC; Peters NH; Veldhuis WB; Gallardo AM; van Diest PJ; Stapper G; van Hillegersberg R; Mali WP; van den Bosch MA
Eur Radiol; 2008 Feb; 18(2):355-64. PubMed ID: 17882425
[TBL] [Abstract][Full Text] [Related]
33. Imaging and Histopathologic Features of BI-RADS 3 Lesions Upgraded during Imaging Surveillance.
Michaels A; Chung CS; Birdwell RL; Frost EP; Giess CS
Breast J; 2017 Jan; 23(1):10-16. PubMed ID: 27612001
[TBL] [Abstract][Full Text] [Related]
34. Screening breast MR imaging: comparison of interpretation of baseline and annual follow-up studies.
Abramovici G; Mainiero MB
Radiology; 2011 Apr; 259(1):85-91. PubMed ID: 21285337
[TBL] [Abstract][Full Text] [Related]
35. Frequency of malignancy seen in probably benign lesions at contrast-enhanced breast MR imaging: findings from ACRIN 6667.
Weinstein SP; Hanna LG; Gatsonis C; Schnall MD; Rosen MA; Lehman CD
Radiology; 2010 Jun; 255(3):731-7. PubMed ID: 20501712
[TBL] [Abstract][Full Text] [Related]
36. MRI for the assessment of malignancy in BI-RADS 4 mammographic microcalcifications.
Bennani-Baiti B; Dietzel M; Baltzer PA
PLoS One; 2017; 12(11):e0188679. PubMed ID: 29190656
[TBL] [Abstract][Full Text] [Related]
37. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications.
Cilotti A; Iacconi C; Marini C; Moretti M; Mazzotta D; Traino C; Naccarato AG; Piagneri V; Giaconi C; Bevilacqua G; Bartolozzi C
Radiol Med; 2007 Mar; 112(2):272-86. PubMed ID: 17361370
[TBL] [Abstract][Full Text] [Related]
38. Breast microcalcifications as type descriptors to stratify risk of malignancy: a systematic review and meta-analysis of 10665 cases with special focus on round/punctate microcalcifications.
Rominger M; Wisgickl C; Timmesfeld N
Rofo; 2012 Dec; 184(12):1144-52. PubMed ID: 22923222
[TBL] [Abstract][Full Text] [Related]
39. Patient compliance and diagnostic yield of 18-month unilateral follow-up in surveillance of probably benign mammographic lesions.
Chung CS; Giess CS; Gombos EC; Frost EP; Yeh ED; Raza S; Birdwell RL
AJR Am J Roentgenol; 2014 Apr; 202(4):922-7. PubMed ID: 24660725
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
